Data Integration for Estimating Subgroup-Specific Conditional Average Treatment Effects (CATEs) Using Coarsened External Information in Randomized Trials
利用粗粒度外部信息估计随机试验的细分亚组处理效应AI 解读 ↓
本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。
DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。
本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。
引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。
关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。
AI 根据所提供的论文材料归类:摘要直接研究随机试验中的亚组条件平均处理效应,并用外部试验信息改进估计,明确属于因果效应异质性分析。
利用粗粒度外部信息估计随机试验的细分亚组处理效应AI 解读 ↓
正在核对关联版本…
正在核对对应版本的资源…
Randomized controlled trials (RCTs) are often underpowered to detect treatment heterogeneity in subgroups defined by cross-classifications of multiple covariates, due to sparse sample sizes in some strata. External RCT data can help, but typically provide treatment effect estimates at a coarser level (e.g., by sex or race) rather than for the finer subgroups of interest (e.g., race-by-sex). We propose a novel James-Stein (JS)-type estimator that borrows strength from such coarsened external estimates to improve estimation of finer subgroup-specific conditional average treatment effects (CATEs) in an internal study, while accommodating potential incompatibility in marginal CATEs across populations. Based on asymptotic theory, we derive a practical analytic variance estimator for the JS estimator that exhibits acceptable empirical performance. Under mild conditions, we show that the proposed estimator uniformly dominates the ordinary least squares (OLS) estimator based on internal data regarding a weighted quadratic loss. Simulation studies demonstrate favorable performance compared with existing shrinkage methods, including empirical Bayes and generalized ridge estimators. We illustrate our method by estimating race-by-sex subgroup CATEs in a tirzepatide weight-loss trial (SURMOUNT-1), borrowing sex-specific and race-specific estimates from two previous semaglutide trials (STEP 1 and STEP 2). The proposed method detects a significantly larger treatment effect on percentage weight loss in the female-White subgroup than in the female-Asian subgroup, a difference not detected using internal data alone.